# Identifying Patients With Asymptomatic Hyperparathyroidism by Serum Calcium and Vitamin D Screening in West Bengal, India

**Authors:** Antarip Bhattacharya, Dhritiman Maitra, Uttam Mondal

PMC · DOI: 10.7759/cureus.81869 · Cureus · 2025-04-08

## TL;DR

The study screens patients in West Bengal for asymptomatic hyperparathyroidism using serum calcium and vitamin D tests, finding a low prevalence but emphasizing early detection to prevent complications.

## Contribution

The study provides population-specific insights into asymptomatic hyperparathyroidism prevalence in West Bengal and highlights the effectiveness of serum screening.

## Key findings

- 85.2% of 6000 patients had normocalcemia with vitamin D deficiency.
- Three hypercalcaemic patients were confirmed to have asymptomatic hyperparathyroidism.
- Asymptomatic hyperparathyroidism prevalence was 0.05% in the studied population.

## Abstract

Background: Primary hyperparathyroidism (PHPT) is the leading cause of hypercalcemia, with solitary parathyroid adenoma responsible for most cases. Many patients with hyperparathyroidism remain asymptomatic, but early detection and parathyroidectomy can prevent complications such as nephrolithiasis, pancreatitis, and bone and kidney disorders. This study emphasizes the importance of screening for asymptomatic hyperparathyroidism to enable timely intervention.

Methods: Serum calcium and Vitamin D3 levels were screened in 6000 outpatients between March 2021 and September 2022. Patients with known hyperparathyroidism, conditions altering calcium metabolism, or those on calcium/Vitamin D supplements were excluded. Vitamin D deficiency was corrected in normocalcemic patients, and follow-up calcium levels were measured. Hypercalcaemic cases underwent additional phosphate and intact parathormone (iPTH) testing. Hyperparathyroidism was confirmed using standard diagnostic criteria, followed by gland localisation and surgery.

Results: Among 6000 patients screened, 85.2% (5112) had normocalcemia with Vitamin D deficiency. Hypercalcemia was initially observed in three patients, with two additional cases identified post-Vitamin D correction. Of the five hypercalcaemic patients, three were confirmed to have high iPTH levels and low phosphate, leading to surgical intervention. Asymptomatic hyperparathyroidism prevalence was 0.05% (3/6000), constituting 15.8% of all PHPT cases encountered during the study period.

Conclusion: While global asymptomatic hyperparathyroidism prevalence is approximately 1%, this study observed a lower incidence (0.05%) in a West Bengal population. Despite this, early screening and intervention are vital to prevent long-term complications and reduce healthcare burdens.

## Linked entities

- **Chemicals:** Vitamin D3 (PubChem CID 5280795)
- **Diseases:** hyperparathyroidism (MONDO:0001741), nephrolithiasis (MONDO:0008171), pancreatitis (MONDO:0004982)

## Full-text entities

- **Diseases:** nephrolithiasis (MESH:D053040), Hypercalcemia (MESH:D006934), Asymptomatic Hyperparathyroidism (MESH:D006961), Vitamin D deficiency (MESH:D014808), parathyroid adenoma (MESH:D010282), bone and kidney disorders (MESH:D007674), pancreatitis (MESH:D010195), PHPT (MESH:D049950)
- **Chemicals:** Vitamin D3 (MESH:D002762), Calcium (MESH:D002118), phosphate (MESH:D010710), Vitamin D (MESH:D014807), parathormone (MESH:D010281), iPTH (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12060077/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12060077/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12060077/full.md

---
Source: https://tomesphere.com/paper/PMC12060077